Release Date: November 25, 2025
Expiration Date: November 25, 2026
Activity Overview
Rapid and thorough biomarker testing is crucial to optimizing individual treatment plans for patients with non–small cell lung cancer (NSCLC). Emerging targeted therapies are improving outcomes for patients whose tumors harbor actionable mutations.
This Community Practice Connection™ program provides an in-depth review of some of the key highlights from an Association of Cancer Care Centers virtual webcast series on current and emerging therapies in NSCLC. This unique and engaging multimedia activity is ideal for the community-based clinician. It focuses on biomarker testing and clinical trial data of targeted agents. The program is designed for those who did not attend the live meeting and to help reinforce learning for those who did.
Target Audience
This educational program is primarily directed toward community-based oncologists involved in the treatment of NSCLC.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Evaluate key biomarkers and their role in guiding targeted therapy selection in non-small cell lung cancer (NSCLC)
- Implement molecular testing strategies to identify actionable mutations in clinical practice
- Apply clinical trial evidence supporting the efficacy and safety of targeted therapies in NSCLC to manage patients with NSCLC with actionable mutations optimally
- Identify optimal strategies to manage adverse events associated with novel targeted therapies in NSCLC
Charu Aggarwal, MD, MPH, FASCO
Leslye M. Heisler Professor for Lung Cancer Excellence
Associate Director, Penn Center for Cancer Care Innovation (PC3I)
Perelman School of Medicine at the University of Pennsylvania
Philadelphia, PA
Disclosures: Consultant: AbbVie, AstraZeneca, Daiichi Sankyo/AstraZeneca, Gilead Sciences, Novocure, Pfizer; Grant/Research Funding (to institution): AstraZeneca/MedImmune, Candel Therapeutics, Daiichi Sankyo/AstraZeneca, Genmab, Loxo@Lilly, Merck Sharp & Dohme; Speaker’s Bureau (to an immediate family member): AstraZeneca
Zofia Piotrowska, MD, MHS
Associate Professor of Medicine, Harvard Medical School
Clinical Co-Director, MGB Thoracic Medical Oncology Program
Mass General Brigham Cancer Institute
Boston, MA
Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: AbbVie, AstraZeneca, Bayer, BlackDiamond, Blueprint Medicines, Boehringer Ingelheim, Daiichi Sankyo, Eli Lilly, Genentech, Gilead, Janssen, Natera, Summit, Taiho, Takeda, Tubulis; Grant/Research Funding: AbbVie, AstraZeneca, Blossom Hill, Blueprint, Cullinan, Daiichi Sankyo, Janssen, Novartis, Nuvalent, Spectrum, SystImmune, Takeda, Tesaro/GSK
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here